Public consultation on aRMM policy

Public consultation on aRMM policy

The Netherlands The Medicines Evaluation Board (MEB) has amended its policy regarding the national implementation of ‘additional Risk Minimization Measures’ (aRMM) (MEB 45). This is still a draft version. The main changes are: 1. Clarification of the...
Public consultation on aRMM policy

Public consultation on labeling policy

The Netherlands The Medicines Evaluation Board (MEB) has amended its policy regarding the labeling of medicines for humans (MEB 6). The MEB recognizes the value that pictograms on the packaging can have to clarify the information. Pictograms on the packaging of...
Changes to product information policy

Changes to product information policy

The Netherlands The Medicines Evaluation Board (MEB) recently revised 2 policy documents relating to the requirements for product information: “labelling of pharmaceutical products” and “Nomenclature of pharmaceutical products”. The revision only applies to medicinal...